Consolidation principles and methods (Details) € in Thousands |
12 Months Ended | |||
|---|---|---|---|---|
|
Dec. 31, 2025
EUR (€)
uSDollarPerEuro
|
Dec. 31, 2024
EUR (€)
uSDollarPerEuro
subsidiary
|
Dec. 31, 2023
EUR (€)
uSDollarPerEuro
|
Dec. 31, 2025
USD ($)
uSDollarPerEuro
parent
|
|
| Disclosure of changes in accounting estimates [line items] | ||||
| Closing foreign exchange rate | uSDollarPerEuro | 1.0389 | 1.1050 | 1.1750 | |
| Average foreign exchange rate | uSDollarPerEuro | 1.1293 | 1.0821 | 1.0816 | |
| Number of parent entities | parent | 1 | |||
| Number of subsidiaries | subsidiary | 2 | |||
| Clinical trial accruals | $ | $ 1,100 | |||
| Research and development expense | € | € 23,115 | € 40,541 | € 38,396 | |
| 1100 Study | ||||
| Disclosure of changes in accounting estimates [line items] | ||||
| Research and development expense | € | € 3,300 | |||